SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-22-012970
Filing Date
2022-05-12
Accepted
2022-05-12 13:47:35
Documents
55
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 912351
2 ex3-4.htm EX-3.4 80713
3 ex31-1.htm EX-31.1 17395
4 ex31-2.htm EX-31.2 17382
5 ex32.htm EX-32 7694
  Complete submission text file 0001493152-22-012970.txt   3267100

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE pvct-20220331.xsd EX-101.SCH 23610
7 XBRL CALCULATION FILE pvct-20220331_cal.xml EX-101.CAL 40459
8 XBRL DEFINITION FILE pvct-20220331_def.xml EX-101.DEF 90182
9 XBRL LABEL FILE pvct-20220331_lab.xml EX-101.LAB 197751
10 XBRL PRESENTATION FILE pvct-20220331_pre.xml EX-101.PRE 158395
49 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 311838
Mailing Address 10025 INVESTMENT DRIVE SUITE 250 KNOXVILLE TN 37932
Business Address 10025 INVESTMENT DRIVE SUITE 250 KNOXVILLE TN 37932 865-769-4011
PROVECTUS BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000315545 (see all company filings)

IRS No.: 900031917 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36457 | Film No.: 22917064
SIC: 2834 Pharmaceutical Preparations